Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988

Cocrystal Pharma, Inc. (NASDAQ: COCP) shares surged 57.84% to $1.61 following the FDA's Fast Track designation for its antiviral candidate CDI-988, aimed at treating and preventing norovirus infections. The Fast Track status will facilitate the drug's development and regulatory review process, allowing for more frequent communication with the FDA and potential eligibility for Priority Review. A Phase 1b challenge study is currently underway at Emory University to assess the candidate's efficacy.